Product
SO-C101
Aliases
SOT101
1 clinical trial
19 indications
Indication
ThyroidIndication
Renal Cell CarcinomaIndication
Lung CancerIndication
Small Cell Lung CancerIndication
Bladder CancerIndication
MelanomaIndication
Merkel Cell CarcinomaIndication
Squamous Cell CarcinomaIndication
Microsatellite Instability HighIndication
Triple-Negative Breast CancerIndication
MesotheliomaIndication
Thymic CancerIndication
Cervical CancerIndication
Bile Duct CancerIndication
Hepatocellular CarcinomaIndication
Ovarian CancerIndication
Stomach CancerIndication
Head and Neck Squamous Cell CarcinomaIndication
Anal CancerClinical trial
A Multicenter Open-label Phase 1/1b Study to Evaluate the Safety and Preliminary Efficacy of SO-C101 as Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced/Metastatic Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-08-01